Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 35
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

Tunable degrees of neurodegeneration in rats based on microsphere‑induced models of chronic glaucoma, Grados ajustables de neurodegeneración en ratas basados ​​en modelos de glaucoma crónico inducidos por microesferas

  • Bravo Osuna, Irene
  • Aragón Navas, Alba
  • García Herranz, David
  • Herrero Vanrell, María Del Rocío
  • Rodrigo María, Jesús
  • Subias, Manuel
  • Montolío, Alberto
  • Cegoñino, José
  • Martínez-Rincón, Teresa
  • Méndez-Martínez, Silvia
  • Pablo Luis, Emilio
  • Pérez del Palomar, Amaya
  • García-Martín, Elena
This study compares four different animal models of chronic glaucoma against normal aging over 6 months. Chronic glaucoma was induced in 138 Long–Evans rats and compared against 43 agedmatched healthy rats. Twenty‑five rats received episcleral vein sclerosis injections (EPIm cohort) while the rest were injected in the eye anterior chamber with a suspension of biodegradable microspheres: 25 rats received non‑loaded microspheres (N‑L Ms cohort), 45 rats received microspheres loaded with dexamethasone (MsDexa cohort), and 43 rats received microspheres co‑loaded with dexamethasone and fibronectin (MsDexaFibro cohort). Intraocular pressure, neuroretinal function, structure and vitreous interface were evaluated. Each model caused different trends in intraocular pressure, produced specific retinal damage and vitreous signals. The steepest and strongest increase in intraocular pressure was seen in the EPIm cohort and microspheres models were more progressive. The EPIm cohort presented the highest vitreous intensity and percentage loss in the ganglion cell layer, the MsDexa cohort presented the greatest loss in the retinal nerve fiber layer, and the MsDexaFibro cohort presented the greatest loss in total retinal thickness. Function decreased differently among cohorts. Using biodegradable microspheres models it is possible to generate tuned neurodegeneration. These results support the multifactorial nature of glaucoma based on several noxa.
Docta Complutense
Publication Artículo científico (JournalArticle)

Chronic Glaucoma Using Biodegradable Microspheres to Induce Intraocular Pressure Elevation. Six-Month Follow-Up

  • Rodrigo, María Jesús
  • García Herranz, David
  • Subías, Manuel
  • Martínez-Rincón, Teresa
  • Mendez-Martínez, Silvia
  • Bravo Osuna, Irene
  • Carretero, Ana
  • Ruberte, Jesús
  • García Feijoo, Julián
  • Pablo, Luis Emilio
  • Herrero Vanrell, María Del Rocío
  • García-Nartín, Elena
To compare two prolonged animal models of glaucoma over 24 weeks of follow-up. A novel pre-trabecular model of chronic glaucoma was achieved by injection of biodegradable poly lactic-co-glycolic acid (PLGA) microspheres (10–20 μm) (Ms20/10) into the ocular anterior chamber to progressively increase ocular hypertension (OHT). Methods: Rat right eyes were injected to induce OHT: 50% received a suspension of Ms20/10 in the anterior chamber at 0, 2, 4, 8, 12, 16 and 20 weeks, and the other 50% received a sclerosing episcleral vein injection biweekly (EPIm). Ophthalmological clinical signs, intraocular pressure (IOP), neuroretinal functionality measured by electroretinography (ERG), and structural analysis of the retina, retinal nerve fiber layer (RNFL) and ganglion cell layer (GCL) protocols using optical coherence tomography (OCT) and histological exams were performed. Results: Both models showed progressive neuroretinal degeneration (p < 0.05), and contralateral eye affectation. The Ms20/10 model showed a more progressive increase in IOP and better preservation of ocular surface. Although no statistical differences were found between models, the EPIm showed a tendency to produce thicker retinal and thinner GCL thicknesses, slower latency and smaller amplitude as measured using ERG, and more aggressive disturbances in retinal histology. In both models, while the GCL showed the greatest percentage loss of thickness, the RNFL showed the greatest and earliest rate of thickness loss. Conclusions: The intracameral model with biodegradable microspheres resulted more like the conditions observed in humans. It was obtained by a less-aggressive mechanism, which allows for adequate study of the pathology over longer periods.
Docta Complutense
Publication Artículo científico (JournalArticle)

Multi‑loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model, Microesferas de PLGA multicargadas como terapia de la neuroretina en un modelo crónico de glaucoma

  • Aragón Navas, Alba
  • Rodrigo, María Jesús
  • Munuera, Inés
  • García Herranz, David
  • Subías, Manuel
  • Villacampa, Pilar
  • García Feijoo, Julián
  • Pablo, Luis
  • García-Martín, Elena
  • Herrero Vanrell, María Del Rocío
  • Bravo Osuna, Irene
This work focused on the co-encapsulation and simultaneous co-delivery of three different neuroprotective drugs in PLGA (poly(lactic-co-glycolic acid) microspheres for the treatment of glaucoma. For formulation optimization, dexamethasone (anti-inflammatory) and ursodeoxycholic acid (anti-apoptotic) were co-loaded by the solid-in-oil-in-water emulsion solvent extraction-evaporation technique as a first step. The incorporation of a water-soluble co-solvent (ethanol) and different amounts of dexamethasone resulted critical for the encapsulation of the neuroprotective agents and their initial release. The optimized formulation was obtained with 60 mg of dexamethasone and using an 80:20 dichloromethane:ethanol ratio. In the second step in the microencapsulation process, the incorporation of the glial cell line-derived neurotrophic factor (GDNF) was performed. The final prototype showed encapsulation efficiencies for each component above 50% with suitable properties for long-term application for at least 3 months. Physicochemical studies were performed by SEM, TEM, DSC, XRD, and gas chromatography. The evaluation of the kinetic release by the Gallagher-Corrigan analysis with Gorrasi correction helped to understand the influence of the co-microencapsulation on the delivery of the different actives from the optimized formulation. The final prototype was tested in a chronic glaucoma animal model. Rats received two intravitreal injections of the neuroprotective treatment within a 24-week follow-up study. The proposed formulation improved retinal ganglion cell (RGC) functionality examined by electroretinography. Also, it was able to maintain a neuroretinal thickness similar to that of healthy animals scanned by in vivo optical coherence tomography, and a higher RGC count on histology compared to glaucomatous animals at the end of the study.
Docta Complutense
Publication Capítulo o parte de un libro (BookPart)

CHAPTER 10: Drug Delivery Systems for the Treatment of Diseases Affecting the Retina and Optic Nerve.

  • Bravo Osuna, Irene
  • Andrés Guerrero, Vanesa
  • Molina Martínez, Irene Teresa
  • Herrero Vanrell, María Del Rocío
Diseases affecting the retina and the optic nerve are the major causes of irreversible blindness in the elderly population. Succesful therapy of these pathologies requires frequent administration of the active molecule close to the retinal target site. Intraocular drug delivery systems (IDDS) are emerging therapeutic tools in the treatment of diseases affecting the posterior segment, as they are able to provide effective concentrations of the drug for a long period, thus avoiding successive injections. Depending on their size, IDDS are classified in implants, microsystems and nanosystems. This chapter covers a general description of the IDDS useful for the treatment of diseases affecting retinal structures. © The Royal Society of Chemistry 2019.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model

  • Rodrigo, María J.
  • Cardiel, María José
  • Fraile, José M.
  • Méndez-Martínez, Silvia
  • Martínez-Rincón, Teresa
  • Subías, Gloria
  • Polo, Víctor
  • Ruberte, J.
  • Ramírez, T.
  • Vispe, Eugenio
  • Luna, C.
  • Mayoral, José A.
  • García-Martín, Elena
Intravitreal administration is widely used in ophthalmological practice to maintain therapeutic drug levels near the neuroretina and because drug delivery systems are necessary to avoid reinjections and sight-threatening side effects. However, currently there is no intravitreal treatment for glaucoma. The brimonidine-LAPONITE® formulation was created with the aim of treating glaucoma for extended periods with a single intravitreal injection. Glaucoma was induced by producing ocular hypertension in two rat cohorts: [BRI-LAP] and [non-bri], with and without treatment, respectively. Eyes treated with brimonidine-LAPONITE® showed lower ocular pressure levels up to week 8 (p < 0.001), functional neuroprotection explored by scotopic and photopic negative response electroretinography (p = 0.042), and structural protection of the retina, retinal nerve fibre layer and ganglion cell layer (p = 0.038), especially on the superior-inferior axis explored by optical coherence tomography, which was corroborated by a higher retinal ganglion cell count (p = 0.040) using immunohistochemistry (Brn3a antibody) up to the end of the study (week 24). Furthermore, delayed neuroprotection was detected in the contralateral eye. Brimonidine was detected in treated rat eyes for up to 6 months. Brimonidine-LAPONITE® seems to be a potential sustained-delivery intravitreal drug for glaucoma treatment., This paper was supported by the Rio Hortega Research Grant M17/00213, PI17/01726, PI17/01946 (Instituto de Salud Carlos III), and by MAT2017-83858-C2-2 MINECO/AEI/ERDF, EU., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Dexamethasone delivery to the ocular posterior segment by sustained-release Laponite formulation

  • Prieto, Esther
  • Cardiel, María José
  • Vispe, Eugenio
  • Idoipe, Miriam
  • García-Martín, Elena
  • Fraile, José M.
  • Polo-Llorens, Vicente
  • Mayoral, José A.
  • Pablo-Júlvez, Luis E.
  • Rodrigo, María J.
This paper presents a novel nanoformulation for sustained-release delivery of dexamethasone (DEX) to the ocular posterior segment using a Laponite (LAP) carrier—DEX/LAP 1:10 w w−1 formulation; 10 mg ml−1. In vivo ocular feasibility and pharmacokinetics after intravitreal (IV) and suprachoroidal (SC) administration in rabbit eyes are compared against IV administration of a DEX solution (1 mg ml−1). Thirty rabbit eyes were injected with the DEX/LAP formulation (15 suprachoroid/15 intravitreous). Ophthalmological signs were monitored at day 1 and at weeks 1–4–12–24 post-administration. Three eyes per sample time point were used to quantify DEX concentration using high-performance liquid chromatography-mass spectrometry. The ocular tissues' pharmacokinetic parameters (lens, vitreous humour, choroid-retina unit and sclera) were studied. DEX/LAP was well tolerated under both administration methods. Peak intraocular DEX levels from the DEX/LAP were detected in the vitreous humour after both deliveries soon after administration. The vitreous area under the curve was significantly greater after both DEX/LAP deliveries (IV: 205 968.47; SC: 11 442.22 ng g−1 d−1) than after IV administration of the DEX solution (317.17 ng g−1 d−1). Intravitreal DEX/LAP delivery extended higher vitreous DEX levels up to week 24 (466.32 ± 311.15 ng g−1). With SC delivery, DEX levels were detectable in the choroid-retina unit (12.04 ± 20.85 ng g−1) and sclera (25.46 ± 44.09 ng g−1) up to week 24. This study demonstrated the intraocular feasibility of both SC and IV administration of the DEX/LAP formulation. The LAP increased the intraocular retention time of DEX when compared with conventional solutions. DEX/LAP could be considered a biocompatible and useful sustained-release formulation for treating posterior-pole eye diseases., This paper was supported by the Carlos III Health Institute (Programme Grant PI12/02285), by Rio Hortega Research Grant M17/00213, PI17/01726, PI17/01946 (Carlos III Health Institute), by MAT2017-83858-C2-2 MINECO/AEI/FEDER, EU, and by the Regional Government of Aragon (E37_17R group, co-financed under FEDER 2014–2020 'Construyendo Europa desde Aragón')., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Monitoring new long-lasting intravitreal formulation for glaucoma with vitreous images using optical coherence tomography

  • Rodrigo, María J.
  • Pérez del Palomar, Amaya
  • Montolío, Alberto
  • Méndez-Martínez, Silvia
  • Subias, Manuel
  • Cardiel, María José
  • Martínez-Rincón, Teresa
  • Cegoñino, José
  • Fraile, José M.
  • Vispe, Eugenio
  • Mayoral, José A.
  • Polo-Llorens, Vicente
  • García-Martín, Elena
This article belongs to the Special Issue Recent Advances in Ophthalmic Drug Delivery., Intravitreal injection is the gold standard therapeutic option for posterior segment pathologies, and long-lasting release is necessary to avoid reinjections. There is no effective intravitreal treatment for glaucoma or other optic neuropathies in daily practice, nor is there a non-invasive method to monitor drug levels in the vitreous. Here we show that a glaucoma treatment combining a hypotensive and neuroprotective intravitreal formulation (IF) of brimonidine–Laponite (BRI/LAP) can be monitored non-invasively using vitreoretinal interface imaging captured with optical coherence tomography (OCT) over 24 weeks of follow-up. Qualitative and quantitative characterisation was achieved by analysing the changes in vitreous (VIT) signal intensity, expressed as a ratio of retinal pigment epithelium (RPE) intensity. Vitreous hyperreflective aggregates mixed in the vitreous and tended to settle on the retinal surface. Relative intensity and aggregate size progressively decreased over 24 weeks in treated rat eyes as the BRI/LAP IF degraded. VIT/RPE relative intensity and total aggregate area correlated with brimonidine levels measured in the eye. The OCT-derived VIT/RPE relative intensity may be a useful and objective marker for non-invasive monitoring of BRI/LAP IF., This study was supported by Carlos III Health Institute, (grants numbers: M17/00213, PI17/01726, PI17/01946), and by MINECO/AEI/ERDF, EU (grants numbers: MAT2017-83858-C2-2)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Laponite for biomedical applications: An ophthalmological perspective

  • Rodrigo, María J.
  • Cardiel, María José
  • Fraile, José M.
  • Mayoral, José A.
  • Pablo-Júlvez, Luis E.
  • García-Martín, Elena
Clay minerals have been applied in biomedicine for thousands of years. Laponite is a nanostructured synthetic clay with the capacity to retain and progressively release drugs. In recent years there has been a resurgence of interest in Laponite application in various biomedical areas. This is the first paper to review the potential biomedical applications of Laponite in ophthalmology. The introduction briefly covers the physical, chemical, rheological, and biocompatibility features of different routes of administration. After that, emphasis is placed on 1) drug delivery for antibiotics, anti-inflammatories, growth factors, other proteins, and cancer treatment; 2) bleeding prevention or treatment; and 3) tissue engineering through regenerative medicine using scaffolds in intraocular and extraocular tissue. Although most scientific research is not performed on the eye, both the findings and the new treatments resulting from that research are potentially applicable in ophthalmology since many of the drugs used are the same, the tissue evaluated in vitro or in vivo is also present in the eye, and the pathologies treated also occur in the eye. Finally, future prospects for this emerging field are discussed., This study was supported by Grants M17/00213, JR22/00057, PI17/01726, PI17/01946, and PI20/00437 (Carlos III Health Institute), and by MAT2017-83858-C2-1, MAT2017-83858-C2-2, PID2020-113281 R B-C2-1, and PID2020-113281 R B-C2-2 funded by (MCIN/AEI/10.13039/501 100 011 033)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Early Changes in Visual Quality and Corneal Structure after DMEK: Does DMEK Approach Optical Quality of a Healthy Cornea?

  • Satue, M.
  • Idoipe, M.
  • Gavin, A.
  • Romero-Sanz, M.
  • Liarakos, V.S.
  • Mateo, A.
  • Garcia-Martin, E.
  • Blasco-Martinez, A.
  • Sanchez-Perez, A.
Purpose. To evaluate early changes in visual function and visual quality parameters after Descemet membrane endothelial keratoplasty (DMEK) and to compare the outcomes with healthy controls. Methods. Thirteen patients who underwent DMEK and 14 controls were evaluated. All subjects underwent visual function evaluation, including visual acuity under photopic and mesopic lighting conditions and contrast sensitivity (CSV) tests CSV 1000 and Pelli-Robson. Corneal parameters were assessed with Oculus Pentacam. Corneal mean keratometry (Km), corneal densitometry values, and low and high order aberrations (LOA and HOA) were recorded. In DMEK patients, all tests were performed before surgery and 1 and 6 months after surgery. Results. In patients who underwent DMEK, photopic visual acuity unproved from 0.59 to 0.31 at 1 month (p = 0.013) and 0.13 at 6 months (p = 0.008); mesopic visual acuity and all contrast sensitivity values (both CSV and Pelli-Robson test) improved significantly in the first month (p < 0.005). A significant decrease was observed in conical density in the 0-2 mm ring (from 43.83 to 35.60, p = 0.043) and mean posterior Km (from -5.84 to -6.80, p = 0.005) in the first month. Corneal HOAs and all corneal densities improved at 6 months after DMEK (p < 0.05). All visual function parameters and corneal aberrations remained lower and higher, respectively, compared with healthy controls (p < 0.05). Corneal densities were comparable with controls at 6 months after DMEK (p > 0.05). Conclusions. Patients undergoing DMEK present visual function improvement and a decrease in corneal density at 1 month after surgery. Decrease in corneal posterior HOAs can be observed at 6 months. However, visual function outcomes and corneal aberrations remained worse compared with healthy controls.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Neurodegeneration in patients with Type 2 Diabetes Mellitus without Diabetic Retinopathy

  • Garcia-Martin, Elena
  • Cipres, Marta
  • Melchor, Isabel
  • Gil-Arribas, Laura
  • Vilades, Elisa
  • Polo, Vicente
  • Rodrigo, María Jesús
  • Satue, María
Purpose. To evaluate neurodegeneration in patients with type 2 diabetes mellitus (DM2) without diabetic retinopathy and to assess the possible role of systemic vascular complications in retinal changes. Methods. Sixty eyes of 60 patients with DM2 and without any signs of diabetic retinopathy and 60 eyes of 60 healthy controls underwent retinal evaluation using Spectralis optical coherence tomography. Macular ganglion cell layer (GCL) and retinal nerve fiber layer (RNFL) were evaluated. Peripapillary RNFL thickness was assessed using Glaucoma and Axonal Analytics applications. Comparison between patients with the presence/absence of systemic vascular complications and different disease duration was made. Results. Macular GCL was reduced in patients compared to controls (p < 0.001). Differences in the macular RNFL thickness were only observed in the outer inferior sector (p = 0.033). A reduction in the peripapillary RNFL (average, inferior, and inferotemporal thickness, p < 0.05 for all three) was observed in patients using both applications. Patients with chronic systemic vascular complications presented a reduction in the temporal RNFL (p = 0.019) compared to patients without complications. The superotemporal RNFL thickness was thinner in patients with longer disease duration. Conclusions. Patients with type 2 DM without diabetic retinopathy and good metabolic control present neurodegeneration affecting neurons in the macular area and axons in different sectors of the optic disc. Systemic vascular complications contributed to further axonal damage in these patients, suggesting a possible role of subclinical ischaemia to retinal neurodegeneration in type 2 DM.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Diagnostic capability of a linear discriminant function applied to a novel Spectralis OCT glaucoma-detection protocol

  • Bambo, M. P.
  • Fuentemilla, E.
  • Cameo, B.
  • Fuertes, I.
  • Ferrandez, B.
  • Güerri, N.
  • Polo, V.
  • Larrosa, J. M.
  • Pablo, L. E.
  • Garcia-Martin, E.
Background Bruch membrane opening–minimum rim width (BMO–MRW) assessment offers a new diagnostic use in glaucoma patients of the Glaucoma Module Premium Edition (GMPE) available for the Spectralis optical coherence tomography (OCT) system. The objective of our research was to evaluate the diagnostic benefits of examining BMO–MRW and peripapillary retinal nerve fibre layer (pRNFL) readings acquired with Spectralis OCT to distinguish between healthy and mild glaucoma patients, comparing those readings with the standard pRNFL application. Moreover, we investigated whether using a particular combination of BMO–MRW and pRNFL parameters with a linear discriminant function (LDF) could further enhance glaucoma diagnosis. Methods One hundred thirty-six eyes from 136 individuals were incorporated into this observational, prospective cross-sectional study: 68 mild primary open-angle glaucoma (POAG) patients according to the Hodapp-Parrish-Anderson criteria (mean deviation between 0 and?-?6?dB) and 68 healthy control subjects selected by Propensity Score Matching. MRW and pRNFL thickness around the disc (diameters: 3.5?mm, 4.1?mm, and 4.7?mm) were obtained using the BMO–MRW protocol, and pRNFL thickness at 3.5?mm was obtained with the standard glaucoma application. The group data were contrasted. One sample was chosen at random to develop the LDF (teaching set: 34 healthy subjects and 34 POAG patients) using a combination of MRW and pRNFL parameters (acquired with the BMO–MRW protocol); the other sample provided a test of how the LDF performed on an independent group (validating set: 34 healthy subjects and 34 POAG patients). The receiver operating curves (ROCs) were plotted for every measurement and contrasted with the proposed LDF. The OCT parameters with the best area under the receiver operating characteristic curve (AUC) were determined. Results Global MRW and pRNFL thicknesses were significantly thinner in the POAG group (p?<? 0.001). The BMO–MRW parameters showed good diagnostic accuracy; the largest AUCs reached 0.875 for the LDF and 0.879 for global RNFL thickness using the standard glaucoma application. There were no statistical differences between the AUCs calculated. Conclusions BMO–MRW parameters show a strong capability to differentiate between mild glaucoma and control eyes. Our LDF based on the new BMO–MRW OCT protocol did not perform better than isolated parameters.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Swept source optical coherence tomography to early detect multiple sclerosis disease. The use of machine learning techniques

  • Pérez del Palomar, Amaya
  • Cegoñino, José
  • Montolío, Alberto
  • Orduna, Elvira
  • Vilades, Elisa
  • Sebastián, Berta
  • Pablo, Luis E.
  • Garcia-Martin, Elena
Objective To compare axonal loss in ganglion cells detected with swept-source optical coherence tomography (SS-OCT) in eyes of patients with multiple sclerosis (MS) versus healthy controls using different machine learning techniques. To analyze the capability of machine learning techniques to improve the detection of retinal nerve fiber layer (RNFL) and the complex Ganglion Cell Layer–Inner plexiform layer (GCL+) damage in patients with multiple sclerosis and to use the SS-OCT as a biomarker to early predict this disease. Methods Patients with relapsing-remitting MS (n = 80) and age-matched healthy controls (n = 180) were enrolled. Different protocols from the DRI SS-OCT Triton system were used to obtain the RNFL and GCL+ thicknesses in both eyes. Macular and peripapilar areas were analyzed to detect the zones with higher thickness decrease. The performance of different machine learning techniques (decision trees, multilayer perceptron and support vector machine) for identifying RNFL and GCL+ thickness loss in patients with MS were evaluated. Receiver-operating characteristic (ROC) curves were used to display the ability of the different tests to discriminate between MS and healthy eyes in our population. Results Machine learning techniques provided an excellent tool to predict MS disease using SS-OCT data. In particular, the decision trees obtained the best prediction (97.24%) using RNFL data in macular area and the area under the ROC curve was 0.995, while the wide protocol which covers an extended area between macula and papilla gave an accuracy of 95.3% with a ROC of 0.998. Moreover, it was obtained that the most significant area of the RNFL to predict MS is the macula just surrounding the fovea. On the other hand, in our study, GCL+ did not contribute to predict MS and the different machine learning techniques performed worse in this layer than in RNFL. Conclusions Measurements of RNFL thickness obtained with SS-OCT have an excellent ability to differentiate between healthy controls and patients with MS. Thus, the use of machine learning techniques based on these measures can be a reliable tool to help in MS diagnosis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Physiological changes in retinal layers thicknesses measured with swept source optical coherence tomography

  • Viladés, E.
  • Perez del Palomar, A.
  • Cegoñino, J.
  • Obis, J.
  • Satue, M.
  • Orduna, E.
  • Pablo, L.E.
  • Ciprés, M.
  • Garcia Martin, E.
Purpose To evaluate the physiological changes related with age of all retinal layers thickness measurements in macular and peripapillary areas in healthy eyes. Methods Wide protocol scan (with a field of view of 12x9 cm) from Triton SS-OCT instrument (Topcon Corporation, Japan) was performed 463 heathy eyes from 463 healthy controls. This protocol allows to measure the thickness of the following layers: Retina, Retinal nerve fiber layer (RNFL), Ganglion cell layer (GCL +), GCL++ and choroid. In those layers, mean thickness was compared in four groups of ages: Group 1 (71 healthy subjects aged between 20 and 34 years); Group 2 (65 individuals aged 35–49 years), Group 3 (230 healthy controls aged 50–64 years) and Group 4 (97 healthy subjects aged 65–79 years). Results The most significant thinning of all retinal layers occurs particularly in the transition from group 2 to group 3, especially in temporal superior quadrant at RNFL, GCL++ and retinal layers (p=0.001), and temporal superior, temporal inferior, and temporal half in choroid layer (p<0.001). Curiously group 2 when compared with group 1 presents a significant thickening of RNFL in temporal superior quadrant (p = 0.001), inferior (p<0.001) and temporal (p = 0.001) halves, and also in nasal half in choroid layer (p = 0.001). Conclusions Excepting the RNFL, which shows a thickening until the third decade of life, the rest of the layers seem to have a physiological progressive thinning. Copyright:
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Dexamethasone delivery to the ocular posterior segment by sustained-release Laponite formulation

  • Prieto, E.
  • Cardiel, M.J.
  • Vispe, E.
  • Idoipe, M.
  • Garcia-Martin, E.
  • Fraile, J.M.
  • Polo, V.
  • Mayoral, J.A.
  • Pablo, L.E.
  • Rodrigo, M.J.
This paper presents a novel nanoformulation for sustained-release delivery of dexamethasone (DEX) to the ocular posterior segment using a Laponite (LAP) carrier - DEX/LAP 1:10 w w-1 formulation; 10 mg ml-1. In vivo ocular feasibility and pharmacokinetics after intravitreal (IV) and suprachoroidal (SC) administration in rabbit eyes are compared against IV administration of a DEX solution (1 mg ml-1). Thirty rabbit eyes were injected with the DEX/LAP formulation (15 suprachoroid/15 intravitreous). Ophthalmological signs were monitored at day 1 and at weeks 1-4-12-24 post-administration. Three eyes per sample time point were used to quantify DEX concentration using high-performance liquid chromatography-mass spectrometry. The ocular tissues'' pharmacokinetic parameters (lens, vitreous humour, choroid-retina unit and sclera) were studied. DEX/LAP was well tolerated under both administration methods. Peak intraocular DEX levels from the DEX/LAP were detected in the vitreous humour after both deliveries soon after administration. The vitreous area under the curve was significantly greater after both DEX/LAP deliveries (IV: 205 968.47; SC: 11 442.22 ng g-1 d-1) than after IV administration of the DEX solution (317.17 ng g-1 d-1). Intravitreal DEX/LAP delivery extended higher vitreous DEX levels up to week 24 (466.32 311.15 ng g-1). With SC delivery, DEX levels were detectable in the choroid-retina unit (12.04 20.85 ng g-1) and sclera (25.46 44.09 ng g-1) up to week 24. This study demonstrated the intraocular feasibility of both SC and IV administration of the DEX/LAP formulation. The LAP increased the intraocular retention time of DEX when compared with conventional solutions. DEX/LAP could be considered a biocompatible and useful sustained-release formulation for treating posterior-pole eye diseases.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Monitoring new long-lasting intravitreal formulation for glaucoma with vitreous images using optical coherence tomography

  • Rodrigo, M.J.
  • Pérez Del Palomar, A.
  • Montolío, A.
  • Mendez-Martinez, S.
  • Subias, M.
  • Cardiel, M.J.
  • Martinez-Rincon, T.
  • Cegoñino, J.
  • Fraile, J.M.
  • Vispe, E.
  • Mayoral, J.A.
  • Polo, V.
  • Garcia-Martin, E.
Intravitreal injection is the gold standard therapeutic option for posterior segment patholo-gies, and long-lasting release is necessary to avoid reinjections. There is no effective intravitreal treatment for glaucoma or other optic neuropathies in daily practice, nor is there a non-invasive method to monitor drug levels in the vitreous. Here we show that a glaucoma treatment combining a hypotensive and neuroprotective intravitreal formulation (IF) of brimonidine–Laponite (BRI/LAP) can be monitored non-invasively using vitreoretinal interface imaging captured with optical coherence tomography (OCT) over 24 weeks of follow-up. Qualitative and quantitative characterisation was achieved by analysing the changes in vitreous (VIT) signal intensity, expressed as a ratio of retinal pigment epithelium (RPE) intensity. Vitreous hyperreflective aggregates mixed in the vitreous and tended to settle on the retinal surface. Relative intensity and aggregate size progressively decreased over 24 weeks in treated rat eyes as the BRI/LAP IF degraded. VIT/RPE relative intensity and total aggregate area correlated with brimonidine levels measured in the eye. The OCT-derived VIT/RPE relative intensity may be a useful and objective marker for non-invasive monitoring of BRI/LAP IF.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Novel use of plga microspheres to create an animal model of glaucoma with progressive neuroretinal degeneration

  • Garcia-Herranz, D.
  • Rodrigo, M.J.
  • Subias, M.
  • Martinez-Rincon, T.
  • Mendez-Martinez, S.
  • Bravo-Osuna, I.
  • Bonet, A.
  • Ruberte, J.
  • Garcia-Feijoo, J.
  • Pablo, L.
  • Garcia-Martin, E.
  • Herrero-Vanrell, R.
Progressive degeneration of neuroretinal tissue with maintained elevated intraocular pressure (IOP) to simulate chronic glaucoma was produced by intracameral injections of poly (lactic-co-glycolic) acid (PLGA) microspheres (Ms) in rat eyes. The right eye of 39 rats received different sizes of PLGA-Ms (2 µL suspension; 10% w/v): 14 with 38–20 µm Ms (Ms38/20 model) and 25 with 20–10 µm particles (Ms20/10 model). This novel glaucoma animal model was compared to the episcleral vein sclerosis (EPI) model (25 eyes). Injections were performed at baseline, two, four and six weeks. Clinical signs, IOP, retina and optic nerve thicknesses (using in vivo optical coherence tomography; OCT), and histological studies were performed. An IOP increment was observed in all three groups, however, the values obtained from the PLGA-Ms injection resulted lower with a better preservation of the ocular surface. In fact, the injection of Ms20/10 created a gentler, more progressive, and more sustained increase in IOP. This IOP alteration was correlated with a significant decrease in most OCT parameters and in histological ganglion-cell count for the three conditions throughout the eight-week follow-up. In all cases, progressive degeneration of the retina, retinal ganglion cells and optic nerve, simulating chronic glaucoma, was detected by OCT and corroborated by histological study. Results showed an alternative glaucoma model to the well-known episcleral vein model, which was simpler to perform, more reproducible and easier to monitor in vivo.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Brimonidine-LAPONITE® intravitreal formulation has an ocular hypotensive and neuroprotective effect throughout 6 months of follow-up in a glaucoma animal model

  • Rodrigo, M.J.
  • Cardiel, M.J.
  • Fraile, J.M.
  • Mendez-Martinez, S.
  • Martinez-Rincon, T.
  • Subias, M.
  • Polo, V.
  • Ruberte, J.
  • Ramirez, T.
  • Vispe, E.
  • Luna, C.
  • Mayoral, J.A.
  • Garcia-Martin, E.
Intravitreal administration is widely used in ophthalmological practice to maintain therapeutic drug levels near the neuroretina and because drug delivery systems are necessary to avoid reinjections and sight-threatening side effects. However, currently there is no intravitreal treatment for glaucoma. The brimonidine-LAPONITE® formulation was created with the aim of treating glaucoma for extended periods with a single intravitreal injection. Glaucoma was induced by producing ocular hypertension in two rat cohorts: [BRI-LAP] and [non-bri], with and without treatment, respectively. Eyes treated with brimonidine-LAPONITE® showed lower ocular pressure levels up to week 8 (p < 0.001), functional neuroprotection explored by scotopic and photopic negative response electroretinography (p = 0.042), and structural protection of the retina, retinal nerve fibre layer and ganglion cell layer (p = 0.038), especially on the superior-inferior axis explored by optical coherence tomography, which was corroborated by a higher retinal ganglion cell count (p = 0.040) using immunohistochemistry (Brn3a antibody) up to the end of the study (week 24). Furthermore, delayed neuroprotection was detected in the contralateral eye. Brimonidine was detected in treated rat eyes for up to 6 months. Brimonidine-LAPONITE® seems to be a potential sustained-delivery intravitreal drug for glaucoma treatment.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Analysis of parainflammation in chronic glaucoma using vitreous-oct imaging

  • Rodrigo, María Jesús
  • Subías, Manuel
  • Montolío, Alberto
  • Méndez-Martínez, Silvia
  • Martínez-Rincón, Teresa
  • Arias, Lorena
  • García-Herranz, David
  • Bravo-Osuna, Irene
  • Garcia-Feijoo, Julián
  • Pablo, Luis
  • Cegoñino, José
  • Herrero-Vanrell, Rocío
  • Carretero, Ana
  • Ruberte, Jesús
  • Garcia-Martin, Elena
  • Pérez Del Palomar, Amaya
Glaucoma causes blindness due to the progressive death of retinal ganglion cells. The immune response chronically and subclinically mediates a homeostatic role. In current clinical practice, it is impossible to analyse neuroinflammation non-invasively. However, analysis of vitreous images using optical coherence tomography detects the immune response as hyperreflective opacities. This study monitors vitreous parainflammation in two animal models of glaucoma, comparing both healthy controls and sexes over six months. Computational analysis characterizes in vivo the hyperreflective opacities, identified histologically as hyalocyte-like Iba-1+ (microglial marker) cells. Glaucomatous eyes showed greater intensity and number of vitreous opacities as well as dynamic fluctuations in the percentage of activated cells (50–250 microns2 ) vs. non-activated cells (10–50 microns2 ), isolated cells (10 microns2) and complexes (>250 microns2 ). Smaller opacities (isolated cells) showed the highest mean intensity (intracellular machinery), were the most rounded at earlier stages (recruitment) and showed the greatest change in orientation (motility). Study of vitreous parainflammation could be a biomarker of glaucoma onset and progression. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Influence of chronic ocular hypertension on emmetropia: Refractive, structural and functional study in two rat models

  • Mendez-Martinez, S.
  • Martínez-Rincón, T.
  • Subias, M.
  • Pablo, L.E.
  • García-Herranz, D.
  • Feijoo, J.G.
  • Bravo-Osuna, I.
  • Herrero-Vanrell, R.
  • Garcia-Martin, E.
  • Rodrigo, M.J.
Chronic ocular hypertension (OHT) influences on refraction in youth and causes glaucoma in adulthood. However, the origin of the responsible mechanism is unclear. This study analyzes the effect of mild-moderate chronic OHT on refraction and neuroretina (structure and function) in young-adult Long-Evans rats using optical coherence tomography and electroretinography over 24 weeks. Data from 260 eyes were retrospectively analyzed in two cohorts: an ocular normotension (ONT) cohort (<20 mmHg) and an OHT cohort (>20 mmHg), in which OHT was induced either by sclerosing the episcleral veins (ES group) or by injecting microspheres into the anterior chamber. A trend toward emmetropia was found in both cohorts over time, though it was more pronounced in the OHT cohort (p < 0.001), especially in the ES group (p = 0.001) and males. IOP and refraction were negatively correlated at week 24 (p = 0.010). The OHT cohort showed early thickening in outer retinal sectors (p < 0.050) and the retinal nerve fiber layer, which later thinned. Electroretinography demonstrated early supranormal amplitudes and faster latencies that later declined. Chronic OHT accelerates emmetropia in Long–Evans rat eyes towards slowly progressive myopia, with an initial increase in structure and function that reversed over time. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Diagnostic ability and capacity of optical coherence tomography-angiography to detect retinal and vascular changes in patients with fibromyalgia

  • Garcia Martin, E.
  • Tello, Á.
  • Vilades, E.
  • Perez-Velilla, J.
  • Cordón, B.
  • Fernandez-Velasco, D.
  • García Campayo, J.
  • Puebla Guedea, M.
  • Satue, M.
Background. To evaluate the neuroretina and retinal vasculature of fibromyalgia (FM) patients and calculate a linear discriminant function (LDF) to improve retinal parameters’ contribution to FM diagnosis. Methods. Fifty FM patients and 232 healthy controls underwent retinal evaluation using swept-source optical coherence tomography (SS-OCT) angiography (Triton plus; Topcon) and spectral domain OCT (SD-OCT) (Spectralis; Heidelberg). The macular (m) and peripapillary (p) retinal nerve fibre layer (RNFL) and ganglion cell layer (GCL) were assessed, as was the macular vascular density. A logistic regression analysis was performed, and an LDF was calculated to evaluate OCT’s contribution to FM diagnosis. Results. With Triton OCT, the patients presented pRNFL thinning in the temporal sector (). Spectralis OCT measurements showed decreased pRNFL in patients in the following sectors: superonasal, ; nasal, ; inferonasal, ; temporal, ; and inferotemporal, . No significant differences were observed in the macular vascular plexus between patients and controls. However, vascular density in the superior sector showed a strong inverse correlation with disease duration (r = −0.978, ). The LDF calculated for Spectralis OCT yielded an area under the ROC curve of 0.968. Conclusions. FM patients present RNFL thinning observable using SS- and SD-OCT. However, these patients show similar vascular density in the macular area to healthy controls. The LDF that combines several RNFL parameters obtained using Spectralis OCT gives this device a powerful ability to differentiate between healthy individuals and individuals with FM.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Analysis of Retinal Layers in Fibromyalgia Patients with Premium Protocol in Optical Tomography Coherence and Quality of Life

  • Cordon, B.
  • Orduna, E.
  • Viladés, E.
  • Garcia-Martin, E
  • Garcia-Campayo, J.
  • Puebla-Guedea, M.
  • Polo, V.
  • Larrosa, J.M.
  • Pablo, L.E.
  • Vicente, M.J.
  • Satue, M.
Purpose To evaluate the inner retinal layers in fibromyalgia (FM) patients compared to control subjects using posterior pole protocol (PPole) analysis in optical coherence tomography (OCT) and to correlate structural retinal changes with subjective quality of life. Methods Seventy-four eyes of healthy subjects and 55 eyes of those with FM were analyzed. All subjects underwent retinal evaluation using the PPole protocol for Spectralis OCT (Heidelberg Engineering) to obtain measurements of the retinal nerve fiber layer (RNFL) and the ganglion cell layer (GCL) in the macular area. The EuroQol (EQ-5D) questionnaire and Fibromyalgia Impact Questionnaire (FIQ) were performed to analyze health-related quality of life. Additionally, the FM group was divided into three groups depending on the disease phenotype (atypical, depressive, and biological). Results Patients with FM presented with a reduction of the RNFL thickness compared to controls in 17/64 cells of the PPole area, and a reduction of the GCL thickness in 47/64 cells. Depressive FM phenotype showed the greatest number of cells with significant reduction compared with the control group in both RNFL and GCL layers. A correlation between temporal-inferior cells of the GCL and the EuroQol 5D questionnaire results was observed. Conclusions Patients with FM present with a reduction of the inner retinal layers in the macular area. This degeneration correlates with disease severity/reduced quality of life in these patients. The PPole protocol for OCT is a non-invasive and fast tool that might help clinicians diagnose and monitor neurodegeneration in FM patients.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Progressive functional and neuroretinal affectation in patients with multiple sclerosis treated with fingolimod

  • Garcia-Martin E.
  • Ruiz de Gopegui E.
  • Satue M.
  • Gil-Arribas L.
  • Jarauta L.
  • Ara J.R.
  • Martin J.
  • Fernandez F.J.
  • Vilades E.
  • Rodrigo M.J.
BACKGROUND: To evaluate the effect of fingolimod in visual function and neuroretinal structures in patients with multiple sclerosis (MS) for a period of 1 year. METHODS: This longitudinal and observational cohort study included 78 eyes of 78 patients with MS treated with fingolimod. All subjects were evaluated every 3 months during 12 months and compared with 32 patients treated with interferon beta. All patients were examined for high-contrast and low-contrast (2.5% and 1.25%) visual acuity (VA), contrast sensitivity vision (CSV) (using Pelli-Robson and CSV-1000E tests), color vision (Farnsworth D-15 and L''Anthony D-15 desaturated tests), and retinal structural measurements (retinal nerve fiber layer [RNFL] and ganglion cell layer [GCL] thickness) using optical coherence tomography (OCT) technology. RESULTS: Patients with MS treated with fingolimod for a period of 1 year showed significant reduction in 100% and 1.25% contrast VA (P = 0.009 and 0.008, respectively), an alteration of contrast sensitivity and color perception (Pelli-Robson test, CSV-1000E test, Farnsworth D-15 desaturated test, and L''Anthony D-15 desaturated test; P < 0.001), GCL thickness reduction (P = 0.007), and an average macular central thickness increase of 2.6 µm (P = 0.006). Patients with MS treated with interferon beta did not show significant changes in visual function tests neither in macular thickness measurements, but they showed a significant reduction in GCL and RNFL thicknesses. The reduction in neuroretinal structures observed by OCT was significantly higher in the interferon-beta group, but patients treated with fingolimod showed a significant increase in macular central thickness and a reduction in low contrast vision (P < 0.001). CONCLUSIONS: Patients with MS treated with fingolimod and with no clinically observable macular edema show a significant change in visual function parameters and average macular central thickness increase compared with those treated with interferon beta. These findings are probably due to subclinical macular edema produced by fingolimod, which might be considered as an indicator for pharmacovigilance of sphingosine-1-phosphate inhibitors to be improved. Copyright © 2020 by North American Neuro-Ophthalmology Society.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Tunable degrees of neurodegeneration in rats based on microsphere-induced models of chronic glaucoma

  • Rodrigo, María Jesús
  • Bravo-Osuna, Irene
  • Subias, Manuel
  • Montolío, Alberto
  • Cegoñino, José
  • Martinez-Rincón, Teresa
  • Mendez-Martinez, Silvia
  • Aragón-Navas, Alba
  • Garcia-Herranz, David
  • Pablo, Luis Emilio
  • Herrero-Vanrell, Rocío
  • Pérez del Palomar, Amaya
  • Garcia-Martin, Elena
This study compares four different animal models of chronic glaucoma against normal aging over 6 months. Chronic glaucoma was induced in 138 Long–Evans rats and compared against 43 aged-matched healthy rats. Twenty-five rats received episcleral vein sclerosis injections (EPIm cohort) while the rest were injected in the eye anterior chamber with a suspension of biodegradable microspheres: 25 rats received non-loaded microspheres (N-L Ms cohort), 45 rats received microspheres loaded with dexamethasone (MsDexa cohort), and 43 rats received microspheres co-loaded with dexamethasone and fibronectin (MsDexaFibro cohort). Intraocular pressure, neuroretinal function, structure and vitreous interface were evaluated. Each model caused different trends in intraocular pressure, produced specific retinal damage and vitreous signals. The steepest and strongest increase in intraocular pressure was seen in the EPIm cohort and microspheres models were more progressive. The EPIm cohort presented the highest vitreous intensity and percentage loss in the ganglion cell layer, the MsDexa cohort presented the greatest loss in the retinal nerve fiber layer, and the MsDexaFibro cohort presented the greatest loss in total retinal thickness. Function decreased differently among cohorts. Using biodegradable microspheres models it is possible to generate tuned neurodegeneration. These results support the multifactorial nature of glaucoma based on several noxa.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Influence of sex on chronic steroid-induced glaucoma: 24-Weeks follow-up study in rats

  • Rodrigo, M. J.
  • Martinez-Rincon, T.
  • Subias, M.
  • Mendez-Martinez, S.
  • Garcia-Herranz, D.
  • Garcia-Feijoo, J.
  • Herrero-Vanrell, R.
  • Pablo, L.
  • Bravo-Osuna, I.
  • Munuera, I.
  • García-Martin, E.
The objective was to evaluate ocular changes based on sex in steroid-induced glaucoma models in rats comparing healthy controls, over 24 weeks follow-up. Eighty-nine Long–Evans rats (38 males and 51 females) with steroid-induced glaucoma were analysed. Two steroid-induced glaucoma models were generated by injecting poly-co-lactic-glycolic acid microspheres loaded with dexamethasone (MMDEX model) and dexamethasone-fibronectin (MMDEXAFIBRO model) into the ocular anterior chamber. Intraocular pressure was measured by rebound tonometer Tonolab®. Neuroretinal function was analysed using dark- and light-adapted electroretinography (Roland consult® RETIanimal ERG), and structure was analysed using optical coherence tomography (OCT Spectralis, Heidelberg® Engineering) using Retina Posterior Pole, Retinal Nerve Fibre Layer and Ganglion Cell Layer protocols over 24 weeks. Males showed statistically (p < 0.05) higher intraocular pressure measurements. In both sexes and models neuroretinal thickness tended to decrease over time. In the MMDEX model, males showed higher IOP values and greatest percentage thickness loss in the Ganglion Cell Layer (p = 0.015). Females receiving MMDEXAFIBRO experienced large fluctuations in thickness, a higher percentage loss (on average) in Retina Posterior Pole (p = 0.035), Retinal Nerve Fibre Layer and Ganglion Cell Layer than aged-matched males, and the highest thickness loss rate by mmHg. Although no difference was found by sex in dark- and light-adapted electroretinography, increased amplitude in photopic negative response was found in MMDEX males and MMDEXAFIBRO females at 12 weeks. Although both glaucoma models used dexamethasone, different intraocular pressure and neuroretinal changes were observed depending on sex and other influential cofactors (fibronectin). Both sex and the induced glaucoma model influenced neuroretinal degeneration.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Laponite for biomedical applications: An ophthalmological perspective

  • Rodrigo, María J.
  • Cardiel, María J.
  • Fraile, José M.
  • Mayoral, José A.
  • Pablo, Luis E.
  • García-Martin, Elena
Clay minerals have been applied in biomedicine for thousands of years. Laponite is a nanostructured synthetic clay with the capacity to retain and progressively release drugs. In recent years there has been a resurgence of interest in Laponite application in various biomedical areas. This is the first paper to review the potential biomedical applications of Laponite in ophthalmology. The introduction briefly covers the physical, chemical, rheological, and biocompatibility features of different routes of administration. After that, emphasis is placed on 1) drug delivery for antibiotics, anti-inflammatories, growth factors, other proteins, and cancer treatment; 2) bleeding prevention or treatment; and 3) tissue engineering through regenerative medicine using scaffolds in intraocular and extraocular tissue. Although most scientific research is not performed on the eye, both the findings and the new treatments resulting from that research are potentially applicable in ophthalmology since many of the drugs used are the same, the tissue evaluated in vitro or in vivo is also present in the eye, and the pathologies treated also occur in the eye. Finally, future prospects for this emerging field are discussed.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Immune Analysis Using Vitreous Optical Coherence Tomography Imaging in Rats with Steroid-Induced Glaucoma

  • Rodrigo, Maria J.
  • Subías, Manuel
  • Montolío, Alberto
  • Martínez-Rincón, Teresa
  • Aragón-Navas, Alba
  • Bravo-Osuna, Irene
  • Pablo, Luis E.
  • Cegoñino, Jose
  • Herrero-Vanrell, Rocío
  • Garcia-Martin, Elena
  • Pérez del Palomar, Amaya
Glaucoma is a multifactorial pathology involving the immune system. The subclinical immune response plays a homeostatic role in healthy situations, but in pathological situations, it produces imbalances. Optical coherence tomography detects immune cells in the vitreous as hyperreflective opacities and these are subsequently characterised by computational analysis. This study monitors the changes in immunity in the vitreous in two steroid-induced glaucoma (SIG) animal models created with drug delivery systems (microspheres loaded with dexamethasone and dexamethasone/fibronectin), comparing both sexes and healthy controls over six months. SIG eyes tended to present greater intensity and a higher number of vitreous opacities (p < 0.05), with dynamic fluctuations in the percentage of isolated cells (10 µm2), non-activated cells (10–50 µm2), activated cells (50–250 µm2) and cell complexes (>250 µm2). Both SIG models presented an anti-inflammatory profile, with non-activated cells being the largest population in this study. However, smaller opacities (isolated cells) seemed to be the first responder to noxa since they were the most rounded (recruitment), coinciding with peak intraocular pressure increase, and showed the highest mean Intensity (intracellular machinery), even in the contralateral eye, and a major change in orientation (motility). Studying the features of hyperreflective opacities in the vitreous using OCT could be a useful biomarker of glaucoma.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Multi-loaded PLGA microspheres as neuroretinal therapy in a chronic glaucoma animal model

  • Aragón-Navas, Alba
  • Rodrigo, Maria Jesus
  • Munuera, Inés
  • García-Herranz, David
  • Subías, Manuel
  • Villacampa, Pilar
  • García-Feijoo, Julián
  • Pablo, Luis
  • Garcia-Martin, Elena
  • Herrero-Vanrell, Rocio
  • Bravo-Osuna, Irene
This work focused on the co-encapsulation and simultaneous co-delivery of three different neuroprotective drugs in PLGA (poly(lactic-co-glycolic acid) microspheres for the treatment of glaucoma. For formulation optimization, dexamethasone (anti-inflammatory) and ursodeoxycholic acid (anti-apoptotic) were co-loaded by the solid-in-oil-in-water emulsion solvent extraction-evaporation technique as a first step. The incorporation of a water-soluble co-solvent (ethanol) and different amounts of dexamethasone resulted critical for the encapsulation of the neuroprotective agents and their initial release. The optimized formulation was obtained with 60 mg of dexamethasone and using an 80:20 dichloromethane:ethanol ratio. In the second step in the microencapsulation process, the incorporation of the glial cell line-derived neurotrophic factor (GDNF) was performed. The final prototype showed encapsulation efficiencies for each component above 50% with suitable properties for long-term application for at least 3 months. Physicochemical studies were performed by SEM, TEM, DSC, XRD, and gas chromatography. The evaluation of the kinetic release by the Gallagher-Corrigan analysis with Gorrasi correction helped to understand the influence of the co-microencapsulation on the delivery of the different actives from the optimized formulation. The final prototype was tested in a chronic glaucoma animal model. Rats received two intravitreal injections of the neuroprotective treatment within a 24-week follow-up study. The proposed formulation improved retinal ganglion cell (RGC) functionality examined by electroretinography. Also, it was able to maintain a neuroretinal thickness similar to that of healthy animals scanned by in vivo optical coherence tomography, and a higher RGC count on histology compared to glaucomatous animals at the end of the study.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Long-term corticosteroid-induced chronic glaucoma model produced by intracameral injection of dexamethasone-loaded PLGA microspheres

  • Rodrigo M.J.
  • Garcia-Herranz D.
  • Aragón-Navas A.
  • Subias M.
  • Martinez-Rincón T.
  • Méndez Martínez S.
  • Cardiel García, M.J.
  • García-Feijoo J.
  • Ruberte J.
  • Herrero-Vanrell R.
  • Pablo Júlvez, L.
  • Garcia Martín, E.
  • Bravo-Osuna I.
Purpose: To evaluate a new chronic glaucoma model produced by intracameral injection of dexamethasone-loaded poly lactic-co-glycolic acid microspheres (Dex-PLGA-Ms) over six months. Methods: Healthy rats received two injections (at baseline and Week 4) of Dex-PLGA-Ms into the anterior chamber of the right eye. Clinical signs and intraocular pressure (IOP) were weekly recorded. The structure of the retina and optic nerve was in vivo evaluated using optical coherence tomography (OCT) every two weeks and functionally using dark- and light-adapted electroretinography at 0–12–24 weeks. Histological studies were also performed. Results: IOP progressively increased up to hypertension (23.22 ± 3.63 mmHg) in both eyes but did so later in left eyes. OCT quantified a decrease in full-thickness retina posterior pole (R), retinal-nerve-fiber layer (RNFL), and ganglion-cell layer (GCL) thickness up to 24 weeks. Right eyes showed higher neuroretinal thickness loss up to week 8. RNFL experienced the highest percentage thickness loss at the inferior-superior axis, while in GCL the inner sectors of the horizontal axis (Nasal-Temporal) suffered the greatest decrease in thickness. Retinal ganglion cell, photoreceptor, and intermediate cell functionality decreased over time. Increased deposition of collagen IV was also found in zonular fibers and the ciliary body. Conclusions: This work shows the usefulness of drug delivery systems, not to treat pathology but to induce it. Only two injections of Dex-PLGA-Ms in the anterior chamber of rat eyes were enough to progressively create ocular hypertension and subsequent functional and structural neuroretinal degeneration, at least over 6 months.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Influence of sex on neuroretinal degeneration: Six-month follow-up in rats with chronic glaucoma

  • Rodrigo, M.J.
  • Martinez-Rincon, T.
  • Subias, M.
  • Mendez-Martinez, S.
  • Pablo, L.E.
  • Polo, V.
  • Aragon-Navas, A.
  • Garcia-Herranz, D.
  • Garcia Feijoo, J.
  • Bravo Osuna, I.
  • Herrero-Vanrell, R.
  • Garcia-Martin, E.
PURPOSE. To evaluate differences by sex in the neuroretina of rats with chronic glaucoma over 24 weeks of follow-up, and to assess by sex the influence on neurodegeneration of different methods of inducing ocular hypertension. METHODS. Forty-six Long-Evans rats-18 males and 28 females-with induced chronic glaucoma were analyzed. Glaucoma was achieved via 2 models: Repeatedly sclerosing the episcleral veins (9 male/14 female) or by injecting poly(lactic-co-glycolic acid) microspheres measuring 20 to 10 µm (Ms20/10) into the anterior chamber (9 male/14 female). The IOP was measured weekly by tonometer; neuroretinal function was recorded by dark/light-adapted electroretinography at baseline and weeks 12 and 24; and structure was analyzed by optical coherence tomography using the retina posterior pole, retinal nerve fiber layer and ganglion cell layer protocols at baseline and weeks 8, 12, 18, and 24.
Docta Complutense
Publication Artículo científico (JournalArticle)

Immune Analysis Using Vitreous Optical Coherence Tomography Imaging in Rats with Steroid-Induced Glaucoma

  • Aragón Navas, Alba
  • Bravo Osuna, Irene
  • Herrero Vanrell, María Del Rocío
  • Rodrigo, María Jesús
  • Subías, Manuel
  • Montolío, Alberto
  • Martínez-Rincón, Teresa
  • Pablo, Luis E
  • Cegoñino, Jose
  • García-Martín, Elena
  • Pérez del Palomar, Amaya
Glaucoma is a multifactorial pathology involving the immune system. The subclinical immune response plays a homeostatic role in healthy situations, but in pathological situations, it produces imbalances. Optical coherence tomography detects immune cells in the vitreous as hyperreflective opacities and these are subsequently characterised by computational analysis. This study monitors the changes in immunity in the vitreous in two steroid-induced glaucoma (SIG) animal models created with drug delivery systems (microspheres loaded with dexamethasone and dexamethasone/fibronectin), comparing both sexes and healthy controls over six months. SIG eyes tended to present greater intensity and a higher number of vitreous opacities (p < 0.05), with dynamic fluctuations in the percentage of isolated cells (10 μm2), non-activated cells (10–50 μm2), activated cells (50–250 μm2) and cell complexes (>250 μm2). Both SIG models presented an anti-inflammatory profile, with non-activated cells being the largest population in this study. However, smaller opacities (isolated cells) seemed to be the first responder to noxa since they were the most rounded (recruitment), coinciding with peak intraocular pressure increase, and showed the highest mean Intensity (intracellular machinery), even in the contralateral eye, and a major change in orientation (motility). Studying the features of hyperreflective opacities in the vitreous using OCT could be a useful biomarker of glaucoma.
Docta Complutense
Publication Artículo científico (JournalArticle)

Influence of Chronic Ocular Hypertension on Emmetropia: Refractive, Structural and Functional Study in Two Rat Models

  • Mendez-Martínez, Silvia
  • Martínez-rincón, Teresa
  • Subías, Manuel
  • Pablo, Luis E
  • García Herranz, David
  • García Feijoo, Julián
  • Bravo Osuna, Irene
  • Herrero Vanrell, María Del Rocío
  • García-Martín, Elena
  • Rodrigo, María Jesús
Chronic ocular hypertension (OHT) influences on refraction in youth and causes glaucoma in adulthood. However, the origin of the responsible mechanism is unclear. This study analyzes the effect of mild-moderate chronic OHT on refraction and neuroretina (structure and function) in young-adult Long-Evans rats using optical coherence tomography and electroretinography over 24 weeks. Data from 260 eyes were retrospectively analyzed in two cohorts: an ocular normotension (ONT) cohort (<20 mmHg) and an OHT cohort (>20 mmHg), in which OHT was induced either by sclerosing the episcleral veins (ES group) or by injecting microspheres into the anterior chamber. A trend toward emmetropia was found in both cohorts over time, though it was more pronounced in the OHT cohort (p < 0.001), especially in the ES group (p = 0.001) and males. IOP and refraction were negatively correlated at week 24 (p = 0.010). The OHT cohort showed early thickening in outer retinal sectors (p < 0.050) and the retinal nerve fiber layer, which later thinned. Electroretinography demonstrated early supranormal amplitudes and faster latencies that later declined. Chronic OHT accelerates emmetropia in Long–Evans rat eyes towards slowly progressive myopia, with an initial increase in structure and function that reversed over time.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Novel Use of PLGA Microspheres to Create an Animal Model of Glaucoma with Progressive Neuroretinal Degeneration

  • Garcia-Herranz, David|||0000-0003-2092-5927
  • Rodrigo Sanjuan, María Jesús|||0000-0002-4009-3075
  • Subías, Manuel|||0000-0002-2344-016X
  • Martínez-Rincón, Teresa|||0000-0002-8891-0417
  • Mendez-Martínez, Silvia|||0000-0001-6072-1545
  • Bravo-Osuna, Irene|||0000-0003-3133-7872
  • Bonet, Aina|||0000-0001-9486-1343
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • García-Feijoo, Julián
  • Pablo, Luis E.|||0000-0003-2389-8282
  • Garcia-Martin, Elena|||0000-0001-6258-2489
  • Herrero-Vanrell, Rocío|||0000-0001-9764-7975
Progressive degeneration of neuroretinal tissue with maintained elevated intraocular pressure (IOP) to simulate chronic glaucoma was produced by intracameral injections of poly (lactic-co-glycolic) acid (PLGA) microspheres (Ms) in rat eyes. The right eye of 39 rats received different sizes of PLGA-Ms (2 µL suspension; 10% w / v): 14 with 38-20 µm Ms (Ms38/20 model) and 25 with 20-10 µm particles (Ms20/10 model). This novel glaucoma animal model was compared to the episcleral vein sclerosis (EPI) model (25 eyes). Injections were performed at baseline, two, four and six weeks. Clinical signs, IOP, retina and optic nerve thicknesses (using in vivo optical coherence tomography; OCT), and histological studies were performed. An IOP increment was observed in all three groups, however, the values obtained from the PLGA-Ms injection resulted lower with a better preservation of the ocular surface. In fact, the injection of Ms20/10 created a gentler, more progressive, and more sustained increase in IOP. This IOP alteration was correlated with a significant decrease in most OCT parameters and in histological ganglion-cell count for the three conditions throughout the eight-week follow-up. In all cases, progressive degeneration of the retina, retinal ganglion cells and optic nerve, simulating chronic glaucoma, was detected by OCT and corroborated by histological study. Results showed an alternative glaucoma model to the well-known episcleral vein model, which was simpler to perform, more reproducible and easier to monitor in vivo.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Chronic Glaucoma Using Biodegradable Microspheres to Induce Intraocular Pressure Elevation. Six-Month Follow-Up

  • Rodrigo Sanjuan, María Jesús|||0000-0002-4009-3075
  • Garcia-Herranz, David|||0000-0003-2092-5927
  • Subías, Manuel|||0000-0002-2344-016X
  • Martínez-Rincón, Teresa|||0000-0002-8891-0417
  • Mendez-Martínez, Silvia|||0000-0001-6072-1545
  • Bravo-Osuna, Irene|||0000-0003-3133-7872
  • Carretero i Romay, Ana|||0000-0001-9377-4926
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • García-Feijoo, Julián
  • Pablo, Luis E.|||0000-0003-2389-8282
  • Herrero-Vanrell, Rocío|||0000-0001-9764-7975
  • Garcia-Martin, Elena|||0000-0001-6258-2489
Background: To compare two prolonged animal models of glaucoma over 24 weeks of follow-up. A novel pre-trabecular model of chronic glaucoma was achieved by injection of biodegradable poly lactic-co-glycolic acid (PLGA) microspheres (10-20 µm) (Ms20/10) into the ocular anterior chamber to progressively increase ocular hypertension (OHT). Methods: Rat right eyes were injected to induce OHT: 50% received a suspension of Ms20/10 in the anterior chamber at 0, 2, 4, 8, 12, 16 and 20 weeks, and the other 50% received a sclerosing episcleral vein injection biweekly (EPIm). Ophthalmological clinical signs, intraocular pressure (IOP), neuroretinal functionality measured by electroretinography (ERG), and structural analysis of the retina, retinal nerve fiber layer (RNFL) and ganglion cell layer (GCL) protocols using optical coherence tomography (OCT) and histological exams were performed. Results: Both models showed progressive neuroretinal degeneration (p < 0.05), and contralateral eye affectation. The Ms20/10 model showed a more progressive increase in IOP and better preservation of ocular surface. Although no statistical differences were found between models, the EPIm showed a tendency to produce thicker retinal and thinner GCL thicknesses, slower latency and smaller amplitude as measured using ERG, and more aggressive disturbances in retinal histology. In both models, while the GCL showed the greatest percentage loss of thickness, the RNFL showed the greatest and earliest rate of thickness loss. Conclusions: The intracameral model with biodegradable microspheres resulted more like the conditions observed in humans. It was obtained by a less-aggressive mechanism, which allows for adequate study of the pathology over longer periods.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Mimicking chronic glaucoma over 6 months with a single intracameral injection of dexamethasone/fibronectin-loaded PLGA microspheres

  • Aragón-Navas, Alba|||0000-0002-7466-8914
  • Rodrigo Sanjuan, María Jesús|||0000-0002-4009-3075
  • Garcia-Herranz, David|||0000-0003-2092-5927
  • Martínez-Rincón, Teresa|||0000-0002-8891-0417
  • Subías, Manuel|||0000-0002-2344-016X
  • Mendez-Martínez, Silvia|||0000-0001-6072-1545
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Pampalona Sala, Judit|||0000-0001-9454-0734
  • Bravo-Osuna, Irene|||0000-0003-3133-7872
  • Pablo, Luis E.|||0000-0003-2389-8282
  • Garcia-Martin, Elena|||0000-0001-6258-2489
  • Herrero-Vanrell, Rocío|||0000-0001-9764-7975
To create a chronic glaucoma animal model by a single intracameral injection of biodegradable poly lactic-co-glycolic acid (PLGA) microspheres (Ms) co-loaded with dexamethasone and fibronectin (MsDexaFibro). MsDexaFibro were prepared by a water-in-oil-in-water emulsion method including dexamethasone in the organic phase and fibronectin in the inner aqueous phase. To create the chronic glaucoma model, an interventionist and longitudinal animal study was performed using forty-five Long Evans rats (4-week-old). Rats received a single intracameral injection of MsDexafibro suspension (10%w/v) in the right eye. Ophthalmological parameters such as clinical signs, intraocular pressure (IOP), neuro-retinal functionality by electroretinography (ERG), retinal structural analysis by optical coherence tomography (OCT), and histology were evaluated up to six months. According to the results obtained, the model proposed was able to induce IOP increasing in both eyes over the study, higher in the injected eyes up to 6 weeks (p < 0.05), while preserving the ocular surface. OCT quantified progressive neuro-retinal degeneration (mainly in the retinal nerve fiber layer) in both eyes but higher in the injected eye. Ganglion cell functionality decreased in injected eyes, thus smaller amplitudes in PhNR were detected by ERG. In conclusion, a new chronic glaucoma animal model was created by a single injection of MsDexaFibro very similar to open-angle glaucoma occurring in humans. This model would impact in different fields such as ophthalmology, allowing long period of study of this pathology; pharmacology, evaluating the neuroprotective activity of active compounds; and pharmaceutical technology, allowing the correct evaluation of the efficacy of long-term sustained ocular drug delivery systems.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Long-term corticosteroid-induced chronic glaucoma model produced by intracameral injection of dexamethasone-loaded PLGA microspheres

  • Rodrigo, MJ.
  • Garcia-Herranz, David|||0000-0003-2092-5927
  • Aragón-Navas, Alba|||0000-0002-7466-8914
  • Subias, M.
  • Martínez-Rincón, Teresa|||0000-0002-8891-0417
  • Mendez-Martínez, S.
  • Cardiel, MJ.
  • García-Feijoo, J.|||0000-0002-7772-5718
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Herrero-Vanrell, Rocío|||0000-0001-9764-7975
  • Pablo, Luis E.|||0000-0003-2389-8282
  • Garcia-Martin, Elena|||0000-0001-6258-2489
  • Bravo-Osuna, Irene|||0000-0003-3133-7872
To evaluate a new chronic glaucoma model produced by intracameral injection of dexamethasone-loaded poly lactic-co-glycolic acid microspheres (Dex-PLGA-Ms) over six months. Healthy rats received two injections (at baseline and Week 4) of Dex-PLGA-Ms into the anterior chamber of the right eye. Clinical signs and intraocular pressure (IOP) were weekly recorded. The structure of the retina and optic nerve was in vivo evaluated using optical coherence tomography (OCT) every two weeks and functionally using dark- and light-adapted electroretinography at 0-12-24 weeks. Histological studies were also performed. IOP progressively increased up to hypertension (23.22 ± 3.63 mmHg) in both eyes but did so later in left eyes. OCT quantified a decrease in full-thickness retina posterior pole (R), retinal-nerve-fiber layer (RNFL), and ganglion-cell layer (GCL) thickness up to 24 weeks. Right eyes showed higher neuroretinal thickness loss up to week 8. RNFL experienced the highest percentage thickness loss at the inferior-superior axis, while in GCL the inner sectors of the horizontal axis (Nasal-Temporal) suffered the greatest decrease in thickness. Retinal ganglion cell, photoreceptor, and intermediate cell functionality decreased over time. Increased deposition of collagen IV was also found in zonular fibers and the ciliary body. This work shows the usefulness of drug delivery systems, not to treat pathology but to induce it. Only two injections of Dex-PLGA-Ms in the anterior chamber of rat eyes were enough to progressively create ocular hypertension and subsequent functional and structural neuroretinal degeneration, at least over 6 months.